Cargando…
Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients
BACKGROUND: The clinical significance of programmed cell death protein-1 (PD-1)-targeted immunotherapy in Chinese patients is understudied. We thus aimed to evaluate the safety and efficacy of PD-1 inhibitors with toripalimab, camrelizumab or sintilimab for Chinese hepatocellular carcinoma (HCC) pat...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576044/ https://www.ncbi.nlm.nih.gov/pubmed/33241036 http://dx.doi.org/10.21037/atm-20-6063 |
_version_ | 1783597934203371520 |
---|---|
author | Chen, Jinzhang Hu, Xiaoyun Li, Qi Dai, Wencong Cheng, Xiao Huang, Wei Yu, Wenxuan Chen, Mian Guo, Yabing Yuan, Guosheng |
author_facet | Chen, Jinzhang Hu, Xiaoyun Li, Qi Dai, Wencong Cheng, Xiao Huang, Wei Yu, Wenxuan Chen, Mian Guo, Yabing Yuan, Guosheng |
author_sort | Chen, Jinzhang |
collection | PubMed |
description | BACKGROUND: The clinical significance of programmed cell death protein-1 (PD-1)-targeted immunotherapy in Chinese patients is understudied. We thus aimed to evaluate the safety and efficacy of PD-1 inhibitors with toripalimab, camrelizumab or sintilimab for Chinese hepatocellular carcinoma (HCC) patients in a real-life cohort. METHODS: We analysed hepatitis B virus (HBV)-associated HCC patients treated with toripalimab, camrelizumab, or sintilimab in a retrospective single-center cohort from November 2018 to June 2020. Efficacy was evaluated with objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), time to tumor progression (TTP), and overall survival (OS). Safety data were also recorded. RESULTS: Seventy patients were finally included in the analysis: 23 were treated with toripalimab, 33 with camrelizumab, and 14 with sintilimab. The mean duration of follow-up was 44.7 (95% CI: 39.9–49.6) weeks and the mean cycles of PD-1 at cutoff were 8.3±8.0 for all patients. The ORR and DCR for the whole cohort were 30% and 72.9%, respectively. Overall, 25 (35.7%) patients had radiological disease progression and 10 (14.3%) patients died during follow-up. Median PFS, median TTP, and median OS had not yet been reached. Most frequent drug-related adverse events (AEs) were rash (27.1%), hypertension (18.6%), fatigue (17.1%), diarrhea (17.1%), paresthesia (15.7%), and nausea (15.7%). CONCLUSIONS: Our findings suggest that (I) PD-1 targeted immunotherapy with toripalimab, camrelizumab, or sintilimab yielded a promising outcome in Chinese HBV patients with HCC and that (II) immunotherapy was well tolerated generally and had manageable side effects. This approach thus warrants further popularization and application in clinical practice. |
format | Online Article Text |
id | pubmed-7576044 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-75760442020-11-24 Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients Chen, Jinzhang Hu, Xiaoyun Li, Qi Dai, Wencong Cheng, Xiao Huang, Wei Yu, Wenxuan Chen, Mian Guo, Yabing Yuan, Guosheng Ann Transl Med Original Article BACKGROUND: The clinical significance of programmed cell death protein-1 (PD-1)-targeted immunotherapy in Chinese patients is understudied. We thus aimed to evaluate the safety and efficacy of PD-1 inhibitors with toripalimab, camrelizumab or sintilimab for Chinese hepatocellular carcinoma (HCC) patients in a real-life cohort. METHODS: We analysed hepatitis B virus (HBV)-associated HCC patients treated with toripalimab, camrelizumab, or sintilimab in a retrospective single-center cohort from November 2018 to June 2020. Efficacy was evaluated with objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), time to tumor progression (TTP), and overall survival (OS). Safety data were also recorded. RESULTS: Seventy patients were finally included in the analysis: 23 were treated with toripalimab, 33 with camrelizumab, and 14 with sintilimab. The mean duration of follow-up was 44.7 (95% CI: 39.9–49.6) weeks and the mean cycles of PD-1 at cutoff were 8.3±8.0 for all patients. The ORR and DCR for the whole cohort were 30% and 72.9%, respectively. Overall, 25 (35.7%) patients had radiological disease progression and 10 (14.3%) patients died during follow-up. Median PFS, median TTP, and median OS had not yet been reached. Most frequent drug-related adverse events (AEs) were rash (27.1%), hypertension (18.6%), fatigue (17.1%), diarrhea (17.1%), paresthesia (15.7%), and nausea (15.7%). CONCLUSIONS: Our findings suggest that (I) PD-1 targeted immunotherapy with toripalimab, camrelizumab, or sintilimab yielded a promising outcome in Chinese HBV patients with HCC and that (II) immunotherapy was well tolerated generally and had manageable side effects. This approach thus warrants further popularization and application in clinical practice. AME Publishing Company 2020-09 /pmc/articles/PMC7576044/ /pubmed/33241036 http://dx.doi.org/10.21037/atm-20-6063 Text en 2020 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Original Article Chen, Jinzhang Hu, Xiaoyun Li, Qi Dai, Wencong Cheng, Xiao Huang, Wei Yu, Wenxuan Chen, Mian Guo, Yabing Yuan, Guosheng Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients |
title | Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients |
title_full | Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients |
title_fullStr | Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients |
title_full_unstemmed | Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients |
title_short | Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients |
title_sort | effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real-world cohort of hepatitis b virus associated hepatocellular carcinoma patients |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576044/ https://www.ncbi.nlm.nih.gov/pubmed/33241036 http://dx.doi.org/10.21037/atm-20-6063 |
work_keys_str_mv | AT chenjinzhang effectivenessandsafetyoftoripalimabcamrelizumabandsintilimabinarealworldcohortofhepatitisbvirusassociatedhepatocellularcarcinomapatients AT huxiaoyun effectivenessandsafetyoftoripalimabcamrelizumabandsintilimabinarealworldcohortofhepatitisbvirusassociatedhepatocellularcarcinomapatients AT liqi effectivenessandsafetyoftoripalimabcamrelizumabandsintilimabinarealworldcohortofhepatitisbvirusassociatedhepatocellularcarcinomapatients AT daiwencong effectivenessandsafetyoftoripalimabcamrelizumabandsintilimabinarealworldcohortofhepatitisbvirusassociatedhepatocellularcarcinomapatients AT chengxiao effectivenessandsafetyoftoripalimabcamrelizumabandsintilimabinarealworldcohortofhepatitisbvirusassociatedhepatocellularcarcinomapatients AT huangwei effectivenessandsafetyoftoripalimabcamrelizumabandsintilimabinarealworldcohortofhepatitisbvirusassociatedhepatocellularcarcinomapatients AT yuwenxuan effectivenessandsafetyoftoripalimabcamrelizumabandsintilimabinarealworldcohortofhepatitisbvirusassociatedhepatocellularcarcinomapatients AT chenmian effectivenessandsafetyoftoripalimabcamrelizumabandsintilimabinarealworldcohortofhepatitisbvirusassociatedhepatocellularcarcinomapatients AT guoyabing effectivenessandsafetyoftoripalimabcamrelizumabandsintilimabinarealworldcohortofhepatitisbvirusassociatedhepatocellularcarcinomapatients AT yuanguosheng effectivenessandsafetyoftoripalimabcamrelizumabandsintilimabinarealworldcohortofhepatitisbvirusassociatedhepatocellularcarcinomapatients |